"Glutathione side effects" is one search with four different answers, because glutathione reaches people by four routes: swallowed, inhaled as a mist, sprayed into the nose, and injected. The published record for each is different in size and in kind.
No FDA-approved medicine delivers glutathione by any of those four routes. On 11 November 2026 FDA's approved-drug data listed glutathione in two application records, both for its oxidised form as one ingredient of a salt solution; the marketed one is BSS Plus (Alcon, NDA 018469), which its label describes as "an intraocular irrigating solution during intraocular surgical procedures" and marks "not for injection or intravenous infusion". So there is no label for glutathione as a treatment, and no adverse-reaction table of the sort an approved medicine has. What exists is a set of trials, most of them small, and two regulator alerts. This page reports what those sources state. It is not medical advice.
The record at a glance
| Route | What the sources record | Largest study read | Kind of source |
|---|---|---|---|
| Oral capsules | Described as well tolerated; no serious adverse effects reported | 60 people, 4 weeks; longest about 6 months | Trial publications |
| Inhaled (nebulised) | Airway narrowing in mild asthma; adverse events similar to placebo in cystic fibrosis | 153 people, 6 months | Trial publications |
| Nasal spray | Three small studies in Parkinson's disease | 45 people, 3 months | Trial publications |
| Injection | Two FDA contamination alerts; anaphylaxis and liver-enzyme reports | At least 30 patients in the 2026 alert | Regulator alerts and trials |
Each row is expanded below with its sources.
Oral glutathione
Five oral studies were read for this page, all from their published abstracts.
| Study | People and length | Daily amount studied | What the abstract says about tolerance |
|---|---|---|---|
| Allen and Bradley 2011 (PMID 21875351) | 40 healthy adults, 4 weeks; 39 completed | 500 mg twice daily | No adverse-event statement in the abstract |
| Arjinpathana 2012 (PMID 20524875) | 60 medical students, 4 weeks; all completed | 500 mg | "Both glutathione and placebo were very well tolerated" |
| Richie 2015 (PMID 24791752) | 54 non-smoking adults, 6 months | 250 mg or 1,000 mg | No adverse-event statement in the abstract |
| Weschawalit 2017 (PMID 28490897) | Healthy women, three arms, 12 weeks | 250 mg (reduced or oxidised form) | "No serious adverse effects throughout the study" |
| GROW trial 2020 (PMID 32960827) | 58 children with cystic fibrosis completed, 24 weeks | Not stated in the abstract | "Safe and well tolerated" |
The amounts are what each trial gave its participants, reported here as trial protocol and not as guidance.
Three things this table does not show:
- No abstract gives a count of adverse events by type. "Well tolerated" is the authors' summary. Healthline's glutathione page, read on 11 November 2026, lists abdominal cramps, bloating, allergic reactions and trouble breathing from bronchial constriction as possible side effects; the cramps and bloating do not appear as numbers in any of the five abstracts, and the breathing effect traces to the inhaled route below.
- The longest studies ran about six months. The authors of the 2012 skin trial wrote that "long-term safety has not been established".
- Two of the five abstracts say nothing about side effects at all, including the largest long-running study in healthy adults.
A separate open-label study in 34 people with fatty liver disease (PMID 28789631) gave 300 mg a day for four months; 29 finished. It had no placebo group, so it cannot separate side effects of glutathione from anything else.
Whether swallowed glutathione reaches the blood intact is a different question, covered in our comparison of injected and oral glutathione.
Inhaled glutathione
This is the route with the clearest documented reaction.
Asthma, 1997. Eight people with mild asthma inhaled 600 mg of nebulised glutathione or saline, one week apart, in a randomised double-blind crossover study (Marrades 1997, PMID 9279219). After saline, FEV1, a standard measure of how much air a person can force out in one second, changed by 1%. After glutathione it fell by 19%, and airway resistance rose 61%. Four patients coughed and three became breathless. The authors tested and ruled out the acidity and concentration of the solution as the cause, and concluded the result "strongly suggests bronchoconstriction provoked by sulfite formation." Salbutamol given beforehand blocked the effect.
Cystic fibrosis. Three trials of inhaled glutathione in cystic fibrosis report no such signal:
| Study | People and length | What the abstract says |
|---|---|---|
| Bishop 2005 (PMID 15653998) | 19 enrolled, 8 weeks | "No adverse events in the treatment group were noted" |
| Griese 2013 (PMID 23631796) | 153 people, 6 months | "The adverse event incidence was similar between glutathione and placebo" |
| Calabrese 2015 (PMID 25458463) | 105 people, 12 months, single-blind | "Well tolerated by all patients" |
The two sets of findings come from different lung conditions, and the asthma study had eight participants. None of them led to an approved inhaled product: the two larger trials report missing their main lung-function targets.
Nasal spray
The intranasal record is three small studies in Parkinson's disease, set out with their tolerability findings on our glutathione nasal spray page. It is not repeated here.
Injection
The injected record is larger and of a different kind. In August 2026 FDA reported at least 30 patients with fever, chills, pain, dizziness and signs of shock after intravenous glutathione that pharmacies had compounded from a dietary-supplement-grade ingredient; it had issued an earlier alert on the same practice in 2019. Trial data and adverse-event database counts sit alongside those alerts.
All of that is documented, with dates and lot numbers, on our glutathione injection side-effects page. The point that matters for this page is that the main documented injection harm comes from the product, and a capsule does not carry it. Amounts reported for injected glutathione are on our glutathione dosage record.
Skin lightening
Much of the interest in glutathione is cosmetic. The two oral skin trials in the table above reported good tolerance over 4 and 12 weeks. A 2016 review (PMID 27088927) recorded that adverse effects from intravenous glutathione had led the Food and Drug Administration of the Philippines to issue a public warning against its off-label use for skin lightening; this page did not open that warning itself. The skin evidence is covered by PeptideGlowJournal's glutathione for skin page.
What is not established
- How often any side effect occurs with oral glutathione. No abstract read here gives a rate.
- Safety beyond about six months of oral use, or beyond twelve months of inhaled use in cystic fibrosis.
- Safety in pregnancy, breastfeeding, or alongside specific medicines. None of the trials read here studied these groups, and without an approved label there is no interaction section to consult.
- Whether the asthma finding applies to current inhaled products. It rests on eight people and one formulation in 1997.
- How glutathione compares with related products. Glutathione's chemistry is in Peptide Lexicon's glutathione entry, and how it compares with the approved drug that supplies its scarcest building block is on our glutathione vs NAC page.
Who makes the decisions
People with asthma, people taking prescription medicines, and anyone considering an injected or inhaled product have the most at stake in this record, and those decisions belong with a clinician. New breathing difficulty, fever or chills after any glutathione product are symptoms for a clinician to assess promptly.
Sources and dates
All PubMed records were read as abstracts on 11 November 2026.
- Marrades RM et al. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. Am J Respir Crit Care Med. 1997;156(2 Pt 1):425–30. PMID 9279219.
- Griese M et al. Inhalation treatment with glutathione in patients with cystic fibrosis. Am J Respir Crit Care Med. 2013;188(1):83–9. PMID 23631796.
- Bishop C et al. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest. 2005;127(1):308–17. PMID 15653998.
- Calabrese C et al. Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis. J Cyst Fibros. 2015;14(2):203–10. PMID 25458463.
- Allen J, Bradley RD. J Altern Complement Med. 2011;17(9):827–33. PMID 21875351.
- Arjinpathana N, Asawanonda P. J Dermatolog Treat. 2012;23(2):97–102. PMID 20524875.
- Richie JP Jr et al. Eur J Nutr. 2015;54(2):251–63. PMID 24791752.
- Weschawalit S et al. Clin Cosmet Investig Dermatol. 2017;10:147–53. PMID 28490897.
- Bozic M et al. (GROW study group). J Pediatr Gastroenterol Nutr. 2020;71(6):771–7. PMID 32960827.
- Honda Y et al. BMC Gastroenterol. 2017;17(1):96. PMID 28789631.
- Sonthalia S et al. Indian J Dermatol Venereol Leprol. 2016;82(3):262–72. PMID 27088927.
- openFDA Drugs@FDA endpoint, query
products.active_ingredients.name:"GLUTATHIONE": 2 application records (NDA 018469, BSS Plus, Alcon, prescription; NDA 020079, discontinued), both listing glutathione disulfide. Read 11 November 2026. - BSS Plus irrigating solution, Alcon, US label, DailyMed listing, label effective 25 January 2024. Read 11 November 2026.
- Healthline, glutathione benefits page, side-effect list as displayed on 11 November 2026 (kind of source: consumer health publisher; cited only for what it lists).
